关键词: 卵巢癌, 靶向治疗, 聚腺苷二磷酸核糖聚合酶抑制剂, 抗血管生成药物, 贝伐珠单抗

Abstract: In recent years，targeted therapy has made great progress in the field of ovarian cancer，which has changed the treatment model of ovarian cancer. Bevacizumab has a definite effect in the initial treatment and maintenance treatment of high-risk advanced ovarian cancer，and in the treatment of platinum-sensitive recurrent ovarian cancer and platinum-resistant recurrent ovarian cancer. It can be combined with chemotherapy or used alone. Poly ADP-ribose polymerase（PARP）inhibitor is currently the most important type of drugs in targeted therapy for ovarian cancer. It exerts an anti-tumor effect through a "synthetic lethal" effect，which significantly improves the prognosis of patients with ovarian cancer. PARP inhibitor has been recommended as the standard treatment to be used in the maintenance treatment of platinum-sensitive recurrent ovarian cancer and first-line maintenance treatment for newly-treated advanced ovarian cancer. We should strictly grasp the indications of targeted therapy and pay attention to the standard management of the whole process，including pre-treatment evaluation，monitoring during and after treatment and timely management of adverse events，so as to reduce the occurrence of related adverse events and increase the safety of long-term treatment. At the same time，it can also improve the patients' medication compliance，which is also the basis for ensuring the efficacy.

Key words: ovarian cancer, targeted therapy, poly ADP-ribose polymerase inhibitor, anti-angiogenic therapy, bevacizumab